Global urethral stricture treatment market, by Type (Posterior Urethral Stricture and Anterior Urethral Stricture), by Treatment (Urethral Dilation, Direct Vision Internal Urethrotomy (DVIU), Urethroplasty (Anastomotic Urethroplasty and Substitution Urethroplasty), and Others), by Disease Indication (Iatrogenic, Idiopathic, Infection-induced, Trauma, and Others), by End User (Hospitals, Ambulatory Surgical Center, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 1,326.0 million in 2019, and is expected to exhibit a CAGR of 6.0%, during the forecast period (2019-2027), as highlighted in a new report published by Coherent Market Insights.

Technological advancement for improving success rate and to lower pain with quick recovery are factors boosting growth of the market. Tissue engineering is one of the current trends in the treatment of urethral stricture. MukoCell, a graft for urethroplasty, developed by UroTiss Europe GmbH is proving as breakthrough option in tissue engineering. Increasing number of anterior urethral stricture cases is expected to be a major factor for growth of the market. According to the National Center for Biotechnology Information (NCBI), in 2019, around 1,242 bulbar urethral strictures were treated with 14 different surgical techniques in Italy. The overall success rate ranged from 87.5% to 14.3% using different techniques. Anterior urethral stricture are the most commonly occurring stricture and are caused due to infection or trauma leading to spongiofibrosis. Anterior urethral stricture mostly occurs in the bulbar urethra which represents around 46.9% of strictures, penile shares around 30.5%, penile & bulbar may represent 9.9%, and panurethral is least representing 4.9% strictures.

Browse 45 Market Data Tables and 37 Figures spread through 195 Pages and in-depth TOC on 'Global Urethral Stricture Treatment Market, by Type (Posterior Urethral Stricture and Anterior Urethral Stricture), by Treatment (Urethral Dilation, Direct Vision Internal Urethrotomy (DVIU), Urethroplasty (Anastomotic Urethroplasty and Substitution Urethroplasty), and Others), by Disease Indication (Iatrogenic, Idiopathic, Infection-induced, Trauma, and Others), by End User (Hospitals, Ambulatory Surgical Center, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027'

To know the latest trends and insights related to Global Urethral Stricture Treatment Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/urethral-stricture-treatment-market-2381

Urethroplasty is a technique used for reconstruction of the infected section of the urethra. According to the Columbia University Irving Medical Center Department of Urology, Urethroplasty is considered as the ‘gold standard’ for urethral reconstruction, as it offers long-lasting results. Urethroplasty has transformed medical procedures by offering benefits such as lower chances of relapse of urethral stricture, reduced threat of inflammation in the area, and improved quality of life. According to the British Association of Urological Surgeons (BAUS) Limited, urethroplasty is the most preferred procedure globally, with a success rate of over 85.0%.

Moreover, adoption of inorganic strategies such as collaborations and acquisitions by major players in the urethral stricture treatment market are expected to drive growth of the market. For instance, in December 2018, Amecath Medical Technologies announced the expansion of its business in Paraguay in collaboration with Infinity International, a healthcare service provider based in Latin America to cater to the growing demand for urological disease treatment.

Furthermore, increasing product approvals by regulatory authorities is also expected to drive the market growth. For instance, in April 2018, Urotronic, Inc. received the U.S. Food and Drug Administration approval for Optilume drug-coated balloon (DCB) catheter for the treatment of male patients suffering from urethral strictures.

Key Takeaways of the Global Urethral Stricture Treatment Market:

  • The global urethral stricture treatment market is expected to exhibit a CAGR of 6.0% during the forecast period (2019-2027), owing to increasing product launches. For instance, in February 2017, Cook Medical, a subsidiary of Cook Group, added two new sets of ureteral stents for percutaneous urinary drainage in its Universa product portfolio. The Universa brand of urinary drainage products also includes ureteral stents and Foley catheters that are available in multiple sizes and configurations to meet patient needs and physician preference.
  • Increasing clinical trials by key players are also estimated to drive the growth of the global urethral stricture treatment market over the forecast period. For instance, in June 2018, Urotronic Inc. collaborated with ClinLogix. LLC to initiate a clinical trial study to establish the safety and effectiveness of the Optilume Stricture Drug Coated Balloon (DCB). The study is expected to complete in November 2024.
  • Major players operating in the global urethral stricture treatment market include Becton, Dickinson and Company, Amecath, Zhejiang Chuangxiang, Medical Technology Co., Ltd, Allium Ltd., SURGIMEDIK, Cook Group, Taewoong Medical Co., Ltd., Teleflex Incorporated, B. Braun Melsungen AG, Coloplast A/S, Boston Scientific Corporation, and Pnn Medical A/S.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner